Program Director, Preemptive Health and Medicine Initiative
Sutha Satkunarajah is the Program Director for Flagship’s Preemptive Medicine and Health Security initiative. He is responsible for coordinating the development, launch, and management of Flagship’s efforts to originate and grow a new generation of companies aimed at preempting, predicting, preventing and/or delaying novel pathogens and chronic diseases.
Sutha brings broad healthcare and project management experience to this role. Before joining Flagship, Sutha led the Program Management Office of REACT, one of the largest COVID-19 surveillance programs in the UK. In this role, Sutha coordinated a team of Principal Investigators, the Department of Health and Social Care (sponsor), and regulator MHRA, to enable delivery and analysis of over 2 million COVID-19 tests to inform UK government policy.
Prior to REACT, Sutha was a Principal at healthcare consulting firm Carnall Farrar and led the analytics for Lord Darzi’s review of Health and Care in 2018 that helped secure a major cash injection in the National Health Service (NHS). He has led major transformation programs across several NHS organizations and accountable care footprints. He spent his early career as an analyst at Oliver Wyman, a management consulting company, and at HgCapital, a European private equity firm.
Sutha graduated from Harvard College with a BA in Cognitive Science, and was an Innovation Fellow at the Institute of Global Health Innovation at Imperial College (2019 – 2021).